Shigeo Ohba1, Yasuhiro Yamada2, Kazuhiro Murayama3, Eriel Sandika4, Hikaru Sasaki4, Seiji Yamada5, Masato Abe6, Mitsuhiro Hasegawa7, Yuichi Hirose7. 1. Department of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan. Electronic address: shigeo.ohba@gmail.com. 2. Department of Neurosurgery, Fujita Health University, Banbuntane Hotokukai Hospital, Aichi, Japan. 3. Department of Radiology, Fujita Health University, Toyoake, Aichi, Japan. 4. Department of Neurosurgery, Keio University School of Medicine, Tokyo, Japan. 5. Department of Pathology, Fujita Health University, Toyoake, Aichi, Japan. 6. Department of Pathology, Fujita Health University, Toyoake, Aichi, Japan; Department of School of Health Sciences, Fujita Health University, Toyoake, Aichi, Japan. 7. Department of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
Abstract
OBJECTIVE: c-Met has been shown to be associated with tumor growth in several human cancers. This study aims to evaluate the correlation between the c-Met expression and histopathologic/clinical characteristics. METHODS: A total of 153 patients with histologically defined World Health Organization grade II-IV diffuse astrocytic and oligodendroglial tumors were analyzed. RESULTS: For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype. Furthermore, it was correlated with overall survival in AO, oligodendroglial tumors, DA, IDH-mutant, DA, IDH-wildtype, and glioblastoma, IDH-wildtype, and tend to be correlated with overall survival in IDH-mutant lower-grade astrocytic tumors. CONCLUSIONS: c-Met expression was revealed to be a useful marker for prognosis prediction in IDH-mutant lower-grade gliomas and glioblastoma, IDH-wildtype, representing a new independent prognostic marker that can be easily measured.
OBJECTIVE: c-Met has been shown to be associated with tumor growth in several human cancers. This study aims to evaluate the correlation between the c-Met expression and histopathologic/clinical characteristics. METHODS: A total of 153 patients with histologically defined World Health Organization grade II-IV diffuse astrocytic and oligodendroglial tumors were analyzed. RESULTS: For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype. Furthermore, it was correlated with overall survival in AO, oligodendroglial tumors, DA, IDH-mutant, DA, IDH-wildtype, and glioblastoma, IDH-wildtype, and tend to be correlated with overall survival in IDH-mutant lower-grade astrocytic tumors. CONCLUSIONS: c-Met expression was revealed to be a useful marker for prognosis prediction in IDH-mutant lower-grade gliomas and glioblastoma, IDH-wildtype, representing a new independent prognostic marker that can be easily measured.
Authors: Jamison Beiriger; Ahmed Habib; Nicolina Jovanovich; Chowdari V Kodavali; Lincoln Edwards; Nduka Amankulor; Pascal O Zinn Journal: Front Oncol Date: 2022-03-10 Impact factor: 6.244
Authors: Kay Ka-Wai Li; Zhi-Feng Shi; Tathiane M Malta; Aden Ka-Yin Chan; Shaz Cheng; Johnny Sheung Him Kwan; Rui Ryan Yang; Wai Sang Poon; Ying Mao; Houtan Noushmehr; Hong Chen; Ho-Keung Ng Journal: Neurooncol Adv Date: 2019-07-17